VTGN News and Press, VistaGen Therapeutics Inc. From 11/17/22

Preclinical data in "gold standard" MPTP non-human primate model of Parkinson's disease show significant reduction of levodopa-induced dyskinesia by AV-101, while maintaining antiparkinsonian activity of levodopa Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceu...

VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its financial results and corpora...

VistaGen Therapeutics, Inc. (VTGN) Q2 2023 Earnings Conference Call November 10, 2022 05:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Conferenc...

VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q2 GAAP EPS of -$0.08. At September 30, 2022, the Company had cash and cash equivalents of approximately $35.3 million. "As a result of the conclusion of certain clinical trial activity and deferral of several resea...

PALISADE-2 Phase 3 trial with PH94B in social anxiety disorder restart preparations underway after independent interim analysis recommends study continue as planned Preliminary analysis of nearly 400 subjects in the final data set for the PALISADE Open Label Study demo...

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that it will host a conferenc...

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursd...

Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced that its Chief Executive Officer Shawn Singh ...

Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chie...

Whether you’re looking for penny stocks to buy right now or to monitor, an excellent place to begin is with a watch list. Researching trending stocks, industries, and the general sentiment is important. But once you’ve done that, it’s time to track your ideas. Today...